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INTRODUCTION 
Chronic inflammation and airway remodeling are 
two key steps in asthma pathophysiology1. 
Transforming growth factor-beta1 (TGF-beta1) is a 
multifunctional cytokine induced in pro- and anti-
inflammatory pathways2. It is produced by many 
types of cells that are activated in the asthmatic 
response. Recent studies highlighted this cytokine 
as an important negative regulator in an 
experimental model of asthma3. In addition, TGF-
beta1 is responsible for subepithelial fibrosis and 
airway smooth muscle cell (ASMC) hypertrophy, 
the principle features of airway wall remodeling in 
asthma2,4. 
Bronchial asthma requires early pharmacological 
treatment and long-term management. Anti-
inflammatory agents, particularly inhaled 
corticosteroids, are currently the most effective 
long-term preventive medication. Moreover, early 
intervention with inhaled corticosteroids plays an 
important role in airway remodeling5. Despite the 
fact that the role of TGF-beta1 in human asthma 
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remains obscure, data derived from animal models 
encouraged further investigation of its suppressive 
mechanisms in order to develop novel therapies for 
asthma3. 
This study was carried out to outline the changes in 
serum TGF-beta1 in children with bronchial asthma 




This work was conducted on 23 asthmatic children 
attending the Pediatric Allergy and Immunology 
Clinic, Children’s Hospital, Ain Shams University, 
in addition to 29 normal healthy children chosen as 
control group from the outpatient clinic.  
Patient group: 
Patients in this study were classified according to 
asthma severity6 into 2 subgroups: 
Mild asthma group: 
This group included 12 children; four with mild 
intermittent and 8 with mild persistent asthma, their 
ages ranged from 5 to 12 years with a mean value of 
7.96 ± 2.63 years. They were 5 males and 7 females. 
They were studied during asthma exacerbations. 
Patients with mild intermittent asthma were on 
inhaled salbutamol 100 mcg/puff by MDI 3 to 4 
times per day according to need as a quick relief 
medication for a duration of 4.63 ± 2.26 years with 
no long term controller therapy. During acute 
exacerbations, they received nebulized salbutamol 
solution in a dose of 0.01-0.02 ml/kg/dose every 6 
hours. After initial response, therapy was continued 
on terbutaline oral preparation in a dose of 0.1-0.2 
mg/kg/day every 8 hours. Oral short-acting 
theophylline (acephylline phenobarbitone) was 
given in a dose of 15-20 mg/kg/day every 8 hours. 
They also received oral antihistamine, promethazine 
in a dose of 0.5 mg/kg/day every 12 hours. Patients 
with mild persistent asthma were maintained on 
sustained-release oral theophylline tablets in a dose 
of 15-20 mg/kg/day every 12 hours and inhaled 
sodium cromoglycate (5 mg/puff by MDI) in a dose 
of 2 puffs/8 hours for a duration of 5.13 ± 1.98 
years. 
Severe persistent asthma group: 
This group included 11 children studied during 
asthma exacerbation, 9 of whom were followed up 
during their symptom free state. Their ages ranged 
from 5 to 13 years with a mean value of 8.68 ± 2.28 
years. They were 5 males and 6 females. All patients 
were on high-dose inhaled beclomethasone 
dipropionate (BDP) (100 mcg/dose), inhaled beta2 
agonist and sustained-release oral theophylline in a 
dose of 15-20 mg/kg/day in two divided doses for a 
duration of 5.95±2.08 years. When needed, they 
received short-acting salbutamol inhaler in a dose of 
3 to 4 puffs per day as quick relief medication. 
Three patients were on oral prednisone in a dose of 
0.5-1 mg/kg/day. For acute asthma exacerbations, 
they intensified their inhaled corticosteroid and 
beta2 agonist therapy. Seven patients needed 
hospitalization and theophylline in a dose of 15-20 
mg/kg/day given by  infusion.  
Control group: 
Twenty-nine healthy children were included in this 
group. They were 14 males and 15 females. Their 
ages ranged from 5 to 13 years with a mean value of 
8.66 ± 2.57 years. Exclusion criteria for controls: 
presence of history or clinical evidence of allergic 
problems, chronic disease or even family history of 
atopy. 
Children in this study were subjected to the 
following: 
1) History taking: laying stress on the duration of 
symptoms, frequency, severity, state of activity, 
precipitating factors, medications received during 
exacerbations and in symptom free state, the 
coexistence of other allergic problems and family 
history of atopy. 
2) Clinical examination with special emphasis on 
weight centile, pulse, blood pressure, temperature, 
respiratory rate and chest examination. 
3) Investigations: 
a- Plain X-ray, postero-anterior view during acute 
asthma exacerbation as needed to exclude 
pneumothorax, collapse or consolidation. 
b- Complete blood counts (CBC) for hemoglobin 
percent (Hb%), total leucocytic count (TLC) and 
absolute eosinophilic count (AEC) on Coulter 
Counter Model T660. Coulter Electronic, Inc., 
Hialeah, Florida, USA. 
c- Total serum IgE by ELISA technique (Genzyme 
Diagnostics, San Carlos, CA94070 USA). 
Owing to its variation with age, total serum IgE 
was taken as the percentage of the actual value 
of the subject in relation to the higher normal for 
age according to Kjellman et al.7. 
d- Biologically active serum transforming growth 
factor-beta1 (TGF-beta1) by ELISA using 
Predicta TGF-beta1 kit, Genzyme Corporation, 
Onekendall Square Cambridge, MAO2139, 
USA. 
Eight patients with mild persistent asthma and 9 
with severe persistent asthma were followed up and 
reevaluated for serum TGF-beta1 during steady state 
asthma. 
Statistical Methods: 
The results of this study were statistically analyzed 
through a standard computer program (Statview, 
version 5, USA). Descriptive statistical analysis was 
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used to describe every parameter as mean, ± SD and 
range. Paired observations were compared using 
paired “t” test. Comparison among groups was done 
employing student “t” test for data showing normal 
distribution. For non-parametric data, comparisons 
were carried out using Wilcoxon signed rank test 
and Mann-Whitney test. Correlation of different 
parameters was performed using the Spearman’s 
correlation test. For all tests, p values less than 0.05 
were considered statistically significant. 
 
RESULTS 
Patients and control groups were comparable 
regarding the age of the subjects (z = 0.5, p>0.05), 
furthermore, the 2 patient groups showed no 
differences in their mean ages (z = 0.7, p>0.05) or 
duration of asthma therapy (t = 1.15, p>0.05).  
On comparing the mild and severe asthma 
groups regarding the AEC and IgE% , no 
significant differences were found (0.58±0.54 
versus 0.89±0.74 x103/mm3, p>0.05 and 310±467.3 
versus 397±468.01%, p>0.05 respectively). 
During acute asthma exacerbations, the mean 
serum TGF-beta1 was significantly elevated for 
mild asthma group in comparison to controls. 
However, the mean serum TGF-beta1 of severe 
persistent asthma group was significantly lower 
(4.23 ± 0.85 ng/ml) than that of controls. Table 1 
and figure 1. 
In patients with mild asthma, a significant drop 
in serum TGF-beta1 was noticed during steady 
state, while in patients with severe persistent 
asthma a significant rise occurred (table 1 and 
figure1). Furthermore, the steady state mean serum 
TGF-beta1 levels of both groups of asthmatic 
children were lower albeit insignificantly different 
from controls.  
Comparison of patients with positive to those 
with negative steroid therapy showed the same 
results as the comparison of the 2 patient groups, 
this is because patients with severe asthma were all 
on steroid therapy and those with mild asthma did 
not receive any steroids.  
A positive correlation, of borderline 
significance, between serum TGF-beta1 and total 
serum IgE% was observed among mild asthamtics 
during acute exacerbations (r = 0.55). Figure 2. 
 
While a non-significant negative correlation 
was found between TGF-beta1 and hemoglobin 
among patients of group I. 
 
Figure 1: Comparison of serum TGF-beta1 during 




Figure 2: Correlation between serum total IgE and 
serum TGF-beta1 during acute asthma 
exacerbations among patients with mild asthma. 
 
Among mild asthmatics, patients with a 
positive family history of asthma had significantly 
lower levels of serum TGF-beta1 during steady 
state compared to those with negative family 
history (4.2±1.04, 12.5±4.33 ng/ml; p<0.05). 
Insignificant differences were encountered during 
acute exacerbations. 
 
Table 1: Comparison of serum TGF-beta1 during and after acute asthma exacerbations among the studied groups. 
























<0.01 >0.05 >0.05 




Serum TGF-beta1 (ng/ml) 
Serum TGF-beta1 (ng/ml) 
Serum total IgE (%) 
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DISCUSSION 
In the present work, a significant rise in the mean 
serum TGF-beta1 was found in mild intermittent 
and mild persistent asthma during exacerbations as 
compared to steady state (p<0.05), and to the 
control group (p<0.01).  Two explanations of this 
finding are suggested; the first is based on the 
report of Chu et al.8 who found that peripheral 
blood neutrophils from asthmatic subjects 
spontaneously released significantly higher levels 
of TGF-beta than those from normal subjects. The 
second explanation is that the rise in serum TGF-
beta1 could be secondary to its rise in the 
respiratory tract during acute asthma as proved by 
Redington et al.9.  
TGF-beta1 is upregulated in response to tissue 
injury and is produced by many cells such as 
activated alveolar macrophages, endothelial cells, T 
and B lymphocytes10. Eosinophils are thought to be 
the main source of TGF-beta1 mRNA in bronchial 
biopsies from acute severe asthma patients11. TGF-
beta1 in turn, has been ranked as a potent mast cell 
chemoattractant12. In addition, it has a similar effect 
on neutrophils, T lymphocytes, and unactivated 
monocytes13. All these effects, superadded to its 
capability of inducing gene transcription of IL1, 
TNF and IL6, account for its proinflammatory 
activity14. However, its exact role in asthma remains 
obscure3. Kim and Lee15 interestingly reported that 
TGF-beta1 has an important role in the elicitation 
of IgE dependent anaphylaxis. It has been shown 
that treatment of passive cutaneous anaphylaxis 
(PCA) sites with neutralizing TGF-beta1 antibodies 
significantly blocked PCA reaction in these sites. 
On the other hand, TGF-beta has been 
demonstrated to have immunosuppressive and anti-
inflammatory effects as well. These contradictory 
effects make it difficult to envisage its overall 
contribution to asthma.   
Contrary to the situation in mild asthma, acute 
exacerbations of severe persistent asthma were 
associated with significantly lower TGF-beta1 
compared to steady state (p<0.05) and to controls 
(p<0.01). Hansen et al.16 were able to abolish 
airway reactivity in mice through genetic 
engineering of Th2 cells to express latent TGF-
beta1. They demonstrated that TGF-beta1 secreting 
T-cells play an important regulatory role in asthma. 
It is speculated that patients with severe asthma 
probably have a defect in TGF-beta1 responses, 
perhaps a genetic one, which results in an 
uncontrolled Th2-induced airway inflammation that 
manifests clinically as severe asthma. 
Another possible explanation is based on the 
fact that all patients in this group were under long-
term therapy with inhaled beclomethasone 
dipropionate (BDP) and 3 of them were additionally 
receiving oral steroids. Furthermore, intensification 
of the doses of inhalation therapy is adopted by 
many of them with the onset of the acute attacks. 
There is accumulating evidence, from 
pharmacokinetic studies, suggesting that absorption 
across the lung vascular bed is an important 
determinant of systemic bioactivity and adverse 
effects, this being particularly the case with inhaled 
corticosteroids, where there is extensive first-pass 
metabolism in the liver but not in the lung17. The 
presence of a putative glucocorticoid responsive 
element (GRE) in the promoter region of the human 
TGF-beta1 gene has been identified18. 
Glucocorticoids induce the production of TGF-beta 
by various cell types including T-cells. The 
biological significance of this finding is not clear, 
but might imply that glucocorticoids by inducing 
TGF-beta, enhance an autocrine control of resting 
and active T-cells that restrict systemic 
inflammation19. The relationship between serum 
cortisone and TGF-beta1 was further clarified by 
Otsuka et al.20, who found a transient increase in 
TGF-beta1 m-RNA expression with raised 
corticosterone levels resulting from long-term 
adrenocorticotrophic hormone (ACTH) therapy. 
Surprisingly, it has been documented that children 
receiving inhaled BDP had lower cortisol secretion 
during the night than those who were not taking 
BDP, with a delayed rise from the nocturnal nadir 
and low early morning levels. Also, inhaled BDP 
produces a dose-dependent adrenal suppression21. 
Thus decreased endogenous cortisol might be the 
reason behind the absence of a rise in serum TGF-
beta1 during acute exacerbations in severe 
asthmatics receiving inhaled steroids. 
The absence of respiratory inflammation in 
normal, non-atopic, non-asthmatic subjects is 
maintained by influences which promote the 
development of non-responsiveness toward inhaled 
aerosols. The cytokine milieu of the healthy 
respiratory tract contributes to this immune non-
responsiveness through the constitutive expression 
of the anti-inflammatory cytokine IL-1022, and 
TGF-beta123.  
It was found, in the present study, that the 
steady state in patients with mild persistent asthma 
was accompanied by a significant drop in the levels 
of TGF-beta1 so that it became insignificantly 
different from that of the control group, achieving a 
cytokine milieu comparable to that found in normal 
non-atopic subjects. This drop in the levels of 
serum TGF-beta1 is probably a consequence of the 
subsidence of the allergic inflammatory response 
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that triggered its release together with other 
cytokines. On the other hand, patients with severe 
persistent asthma experienced a mild but significant 
rise in serum TGF-beta1 as they entered the steady 
state. It seems that TGF-beta1 secretion has been 
restrained during exacerbation by an inhibitory 
influence, perhaps that of inhaled steroid therapy. 
This influence is relieved during steady state so that 
the levels of TGF-beta1 in serum achieved 
normality.  
Many reports emphasize the role of TGF-beta1 
in tissue remodeling and repair. However, 
overproduction and activation have been linked to 
the fibrotic complications associated with chronic 
inflammatory conditions such as idiopathic 
pulmonary fibrosis and pulmonary tuberculosis. 
Fortunately, high levels of TGF-beta1 of mild 
asthma patients are not maintained through steady 
state and the levels in severe asthma patients do not 
exceed the normal limit, otherwise, the course of 
illness in these patients would have changed into 
one of chronic obstructive airway disease. 
Interestingly, mild intermittent and mild 
persistent asthma patients with positive family 
history of asthma had significantly lower levels of 
serum TGF-beta1 during steady state compared to 
those with negative family history of the same 
group (p<0.05). Insignificantly higher levels were 
also encountered during acute exacerbations 
(p>0.05). Hobbs et al.24 demonstrated the presence 
of polymorphism in the promoter region of the IL-
10 gene and four in the TGF-beta promoters (3 in 
TGF-beta1 and 1 in TGF-beta2) in DNA taken from 
families with asthmatic proband. These families 
have been identified by the presence of a pregnant 
mother with asthma, and the proband is the child 
who has been followed up since birth. It is 
speculated that asthmatic patients with positive 
family history of asthma have some form of TGF-
beta polymorphism that is evidenced by a lower 
serum TGF-beta1. This polymorphism in TGF-beta 
gene might also explain the low but statistically 
insignificant differences in serum TGF-beta1 in the 
studied asthma groups during steady state when 
compared to controls (9.21±9.81 vs. 21.81±22.09 
ng/ml respectively). 
A significant negative correlation of serum 
TGF-beta1 with Hb% during steady state (r = -0.64, 
p>0.05) in mild asthmatics was found in the present 
study. It has been previously shown that in vivo 
administration of TGF-beta1 either systemically or 
locoregionally resulted in suppression of 
hematopoiesis. Furthermore, depending on the 
target cell, TGF-beta1 can enhance or inhibit 
proliferation. Early erythroid and myeloid 
progenitors are markedly inhibited in the presence 
of TGF-beta1 whereas more differentiated myeloid 
progenitors forming granulocytes, macrophages, 
granulocyte-macrophage colonies and erythroid 
progenitors are not inhibited by TGF-beta125. 
Zermati et al.26 studied the mechanisms by which 
TGF-beta 1 inhibits erythropoiesis using in vitro 
serum-free system of human red blood cell 
production. They found that TGF-beta 1 is a 
paradoxical inhibitor of erythropoiesis that acts by 
blocking proliferation and accelerating 
differentiation of erythroid progenitors. 
It is concluded that the relationship of TGF-
beta1 to asthma is not fully understood. The 
behavior of serum TGF-beta1 in acute asthma 
exacerbation is dependent on the severity of 
asthma: it was significantly higher in mild asthma, 
while in severe asthma it was low, perhaps, related 
to an inherent defect in TGF-beta1 secretion or to 
steroid inhalation therapy. The tendency towards 
normality during steady state might signify a good 
prognosis in terms of the remote outcome. 
However, further longitudinal studies are needed to 
confirm this and to throw more light on the role of 
TGF-beta1 in asthma. 
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